



(51) International Patent Classification:

C07K 16/30 (2006.01) A61K 31/475 (2006.01)
 A61K 39/395 (2006.01) A61K 31/555 (2006.01)
 A61P 35/00 (2006.01) A61K 31/675 (2006.01)
 A61P 43/00 (2006.01) A61K 31/7048 (2006.01)
 A61K 31/00 (2006.01) A61K 33/243 (2019.01)
 A61K 33/00 (2006.01) A61K 38/19 (2006.01)

(21) International Application Number:

PCT/GB2021/051721

(22) International Filing Date:

06 July 2021 (06.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20305766.6 06 July 2020 (06.07.2020) EP

(71) Applicant: **EUSA PHARMA (UK) LIMITED** [GB/GB];
 Breakspear Park, Breakspear Way, Hemel Hempstead Hert-
 fordshire HP2 4TZ (GB).

(72) Inventors: **LODE, Holger Nikolaus**; Universitätsmedi-
 zin Greifswald, Leiter Allgemeine Pädiatrie und
 Pädiatrische Hämatologie/Onkologie, Ferdinand-Sauer-
 bruch-Straße, 17475 Greifswald (DE). **LADENSTEIN,**
Ruth; St. Anna Kinderkrebsforschung, CHILDREN'S

CANCER RESEARCH INSTITUTE, Zimmermannplatz
 10, 1090 Wien (AT).


(74) Agent: **LINEHAN, Sheena Alice**; Potter Clarkson, The
 Belgrave Centre, Talbot Street, Nottingham Notting-
 hamshire NG1 5GG (GB).

(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
 HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
 NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
 SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: METHOD FOR TREATING A GD2-POSITIVE CANCER

Figure 1 Study Schema



(57) **Abstract:** A method of treating a newly diagnosed neuroblastoma in a patient by administering chimeric anti-GD2 antibody dinutuximab beta to the patient in combination with induction chemotherapy. The chimeric anti-GD2 antibody dinutuximab beta is administered at a cumulative dose of up to 500 mg/m², and/or in a dose of up to 100 mg/m² per cycle during one or more cycles of induction chemotherapy, and/or at a treatment density of up to 5 mg/m²/day.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*